Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

No intervention

Judith R Kroep, MD PhD

A F de Groot, MD

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.

Tumor material, ascites and blood samples before and/or during therapy.

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Leiden University Medical Center

Principal Investigator MD PhD

Respiratory Tract (Lung and Bronchial) Diseases

Symptoms and General Pathology

Carcinoma, Non-Small-Cell Lung

Hypoxia

Carcinoma, Bronchogenic

Bronchial Neoplasms

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Egesta Lopci, MD

This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.

This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with radical intent at our center.

We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to hypoxic and immune-related markers at immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.

Role of FDG PET, Immune and Hypoxic Marker in NSCLC

FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale

Istituto Clinico Humanitas

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Determining Prognostic Immune Markers in Patients With Ovarian Cancer	NCT03862677	Epithelial Ovar...	No intervention	18 Years -	Leiden University Medical Center
Role of FDG PET, Immune and Hypoxic Marker in NSCLC	NCT02519062	Carcinoma, Non-...	No intervention	18 Years -	Istituto Clinico Humanitas
Role of FDG PET, Immune and Hypoxic Marker in NSCLC	NCT02519062	Carcinoma, Non-...	No intervention	18 Years -	Istituto Clinico Humanitas

Spots Global Cancer Trial Database for immune markers